Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-26
2006-09-26
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S407000, C548S374100, C548S376100, C548S377100
Reexamination Certificate
active
07112601
ABSTRACT:
Compounds of Formula I are disclosed which inhibit hepatitis C NS5B RNA-dependent RNA polymerase and are useful for treating hepatitis C. Compositions and methods of using these compounds are also disclosed
REFERENCES:
patent: 6045773 (2000-04-01), Isakson et al.
patent: 1 256 628 (2002-11-01), None
patent: WO 00/06529 (2000-02-01), None
patent: WO0006529 (2000-02-01), None
patent: WO 00/10573 (2000-03-01), None
patent: WO 00/13708 (2000-03-01), None
patent: WO 00/18231 (2000-04-01), None
patent: WO 01/32153 (2001-05-01), None
patent: WO 01/47883 (2001-07-01), None
patent: WO 02/04425 (2002-01-01), None
patent: WO 02/100851 (2002-12-01), None
patent: WO 03/007945 (2003-01-01), None
patent: WO 03/010141 (2003-02-01), None
Lauer, G.M., et al., “Hepatitic C Virus Infection,” The New England Journal of Medicine, vol. 345, No. 1, Jul. 5, 2001, pp. 41-52.
Poynard, T., et al., “Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus,” The Lancet, vol. 352, Oct. 31, 1998, pp. 1426-1432.
Zeuzem, S., et al., “Peginterferon Alfa-2a in Patients with Chronic Hepatitis C,” The New England Journal of Medicine, vol. 343, No. 23, Dec. 7, 2000, pp. 1666-1672.
Kolykhalov, A., et al., “Hepatitus C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3′ Nontranslated Region Are Essential for Virus Replication In Vivo,” Journal of Virology, vol. 74, No. 4, Feb. 2000, pp. 2046-2051.
Duncia, J.V., et al., “Three Synthetic Routes to a Sterically Hindered Tetrazole. A New One-Step Mild Converstion of an Amide into a Tetrazole,” Journal of Organic Chemistry, 56, 1991, pp. 2395-2400.
Herr, R.J., “5-Substituted-1H-tetrazoles as Carboxylic Acid Isosteres: Medicinal Chemistry and Synthetic Methods,” Bioorganic and Medicinal Chemistry, 10, 2002, pp. 3379-3393.
Koguro, K., et al., “Novel Synthesis of 5-Substituted Tetrazoles from Nitriles,” Synthesis, Jun. 1998, pp. 910-914.
Sturino, C.F., et al., “A Convenient Method for the Preparation of Acylsulfonamide Libraries,” Tetrahedron Letters, 39, 1998, pp. 5891-5894.
Drummond, J.T., et al., “Convenient Procedure for the Preparation of Alkyl and Aryl Substituted N-(Aminoalkylacyl)Sulfonamides,” Tetrahedron Letters, vol. 29, No. 14, pp. 1653-1656, 1988.
Cossu, S., et al., “Unusual Reactivity of 4-Carboxyamido-2-oxazoline Systems: New Synthesis of Optically Active N-Sulphonyl Derivatives,” Tetrahedron, vol. 50, No. 17, pp. 5083-5090, 1994.
Mantlo, N.B., et al., “Imidaz[4,5-b]Pyridine-Based AT1/AT2Angiotesin II Receptor Antagonists,” Bioorganic and Medicinal Chemistry Letters, vol. 4, No. 1, pp. 17-22, 1994.
Yohara, Y., et al., “A New Class of Angiotesin II Receptor Antagonists with a Novel Acidic Bioisostere,” Bioorganic and Medicinal Chemistry, vol. 5, No. 17, pp. 1903-1908, 1995.
Kim, D., et al., “Evaluation of Heterocyclic Acid Equivalents as Tetrazole Replacements in Imidazopyridine-Based Nonpeptide Angiotensin II Receptor Antagonists,” Bioorganic and Medicinal Chemistry, vol. 4, No. 1, pp. 41-44, 1994.
Gezginci, M.H., et al., “Antimycobacerial Activity of Substituted Isosteres of Pyridine- and Pyrazinecarboxylic Acids. 2.,” Journal of Medicinal Chemistry, 2001, 44, pp. 1560-1563.
Soll, R.M., et al., “3-Hydroxy-3-Cyclobutene-1,2-Dione: Application of a Novel Carboxylic Acid Bioisostere to an In-Vivo Active Non-Tetrazole Angiotensin-II Antagonist,” Bioorganic and Medicinal Chemistry, vol. 3, No. 4, pp. 757-760, 1993.
Liebeskind, L.S., et al., “3-Stannylcyclobutenediones as Nucleophilic Cyclobutenedione Equivalents. Synthesis of Substituted Cyclobutenediones and Cyclobutenedione Monoacetals and the Beneficial Effect of Catalytic Copper Iodide on the Stille Reaction,” Journal of Organic Chemistry, 1990, 55, pp. 5359-5364.
Kehler, J., et al., “Novel Phosphinic and Phosphonic Acid Analogues of the Anticonvulsant Valproic Acid,” Bioorganic and Medicinal Chemistry Letters, 10, 2000, pp. 2547-2548.
Golebiowski, A., et al., “Solid Supported Synthesis of Hydroxamic Acids,” Tetrahedron Letters, 39, 1998, pp. 3397-3400.
Taliani, M., et al., “A Continuous Assay of Hepatitis C Virus Protease Based on Resonance Energy Transfer Depsipeptide Substrates,” Analytical Biochemistry, 240, 1996, pp. 60-67.
Tan, S-L, et al., “Hepatitis C Therapeutics: Current Status and Emerging Strategies,” Nature Reviews/Drug Discovery, vol. 1, Nov. 2002, pp. 867-881.
Still, W.C., et al., “Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution,” Journal of Organic Chemistry, vol. 43, No. 14, 1978, pp. 2923-2925.
Gridnev, A.A., et al., “Synthesis of 1-Alkylimidazoles,” Synthetic Communications, 24, 11, 1994, pp. 1547-1555.
Douty Brent D.
Glunz Peter W.
Martin Scott W.
Romine Jeffrey
Bristol--Myers Squibb Company
Epperson James
Grazier Nyeemah
Saeed Kamal A.
LandOfFree
Cycloalkyl heterocycles for treating hepatitis C virus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cycloalkyl heterocycles for treating hepatitis C virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cycloalkyl heterocycles for treating hepatitis C virus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3574744